FDA Extends Review of FILSPARI sNDA for FSGS, Setting New PDUFA Date for April 2026

summarizeSummary

Travere Therapeutics announced the FDA extended the review of its sNDA for FILSPARI in FSGS to April 13, 2026, following a Major Amendment submission for clinical benefit characterization.

check_boxKey Events

• FDA Review Extended for FILSPARI in FSGS

  The U.S. Food and Drug Administration (FDA) has extended the review timeline for Travere Therapeutics' supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS).

• New PDUFA Target Action Date Set

  The new Prescription Drug User Fee Act (PDUFA) target action date for the sNDA is now April 13, 2026.

• Extension Due to Major Amendment

  The extension follows the submission of responses requested by the FDA to further characterize the clinical benefit of FILSPARI, which the FDA determined constituted a Major Amendment to the sNDA.

• No Safety or Manufacturing Concerns Raised

  The filing explicitly states that no additional information relating to the safety or manufacturing of FILSPARI has been requested by the FDA.

auto_awesomeAnalysis

The FDA's decision to extend the review period for FILSPARI's supplemental New Drug Application (sNDA) for focal segmental glomerulosclerosis (FSGS) introduces a delay in potential market entry for this first-in-class therapy. While the extension is due to the FDA requiring more data on clinical benefit rather than safety or manufacturing issues, it signals increased scrutiny and pushes back the PDUFA target action date to April 13, 2026. Investors should monitor the company's communication regarding the additional data provided and any further FDA feedback.